Warfarin therapy in the HIV medical home model: Low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals

AIDS Patient Care and STDs

Volumn 26, Issue 8, 2012, Pages 454-462

  Anderson, Albert M ^a,b   Chane, Tanea ^b   Patel, Manish ^b   Chen, Shuo ^c   Xue, Wenqiong ^c   Easley, Kirk A ^c  

^a EMORY UNIVERSITY   (United States)

^b GRADY HEALTH SYSTEM   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; DEEP VEIN THROMBOSIS; FEMALE; FIBROMA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART VALVE REPLACEMENT; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NURSING HOME; PATIENT COMPLIANCE; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; ANTI-HIV AGENTS; ANTICOAGULANTS; BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HIV SEROPOSITIVITY; HUMANS; INTERNATIONAL NORMALIZED RATIO; LOPINAVIR; MALE; MEDICATION ADHERENCE; PATIENT-CENTERED CARE; RETROSPECTIVE STUDIES; RITONAVIR; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOSIS; WARFARIN;

EID: 84864722466     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2012.0068     Document Type: Article

References (32)

1. Crum-Cianflone NF, Weekes J, Bavaro M. Review: Thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDs 2008; 22:771-778.
2. Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci 2008;336:402-406.
3. Saber AA, Aboolian A, LaRaja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: A study of 45 patients with lower extremity involvement. Am Surg 2001; 67:645-647.
4. Funderburg NT, Mayne E, Sieg SF et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: Relationship to in vivo coagulation and immune activation. Blood 2010;115:161-167.
5. Saif MW, Bona R, Greenberg B. AIDS and thrombosis: Retrospective study of 131 HIV-infected patients. AIDS Patient Care STDs 2001;15:311-320.
6. Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000;14:321-324.
7. Dillmon MS, Saag MS, Hamza SH, Adler BK, Marques MB. Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: Case reports and review of the literature. AIDS Res Hum Retroviruses 2005;21:753-756.
8. Galrao L, Brites C, Atta ML et al. Antiphospholipid antibodies in HIV-positive patients. Clin Rheumatol 2007;26: 1825-1830.
9. Ahonkhai AA, Gebo KA, Streiff MB, Moore RD, Segal JB. Venous thromboembolism in patients with HIV/AIDS: A case-control study. J Acquir Immune Defic Syndr 2008;48: 310-314.
10. Jong E, Louw S, van Gorp EC, Meijers JC, ten CH, Jacobson BF. The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost 2010;104:1228-1234.
11. Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: A case series. Clin Infect Dis 2004;39:1214-1222.
12. Palella FJ, Jr., Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
13. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):454S-545S.
14. Hirsh J, Dalen J, Anderson DR et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 Suppl):8S-21S.
15. Liedtke MD, Rathbun RC. Warfarin-antiretroviral interactions. Ann Pharmacother 2009;43:322-328.
16. Bonora S, Lanzafame M, D'Avolio A, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 2008;46:146-147.
17. Goldstein KM, Gluckman S, Mounzer K. Challenge of coadministering antiretroviral therapy and oral anticoagulants in HIV-positive patients. AIDS Read 2008;18:480-489.
18. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998; 32:1299-1302.
19. Saag MS. Ryan White: An unintentional home builder. AIDS Read 2009;19:166-168.
20. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):160S-198S.
21. Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):593S-629S.
22. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):546S-592S.
23. Williamson JM, Lipsitz SR, Kim KM. GEECAT and GEEGOR: Computer programs for the analysis of correlated categorical response data. Comput Methods Programs Biomed 1999;58:25-34.
24. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
25. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-1166.
26. Penning-van Beest FJ, van ME, Rosendaal FR, Stricker BH. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001;86: 569-574.
27. Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 2008;16:94-98.
28. Platt AB, Localio AR, Brensinger CM, et al. Risk factors for nonadherence to warfarin: Results from the IN-RANGE study. Pharmacoepidemiol Drug Saf 2008;17:853-860.
29. Penning-van Beest FJ, van ME, Rosendaal FR, Stricker BH. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001;69:451-457.
30. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: Review of the literature and implications for treatment monitoring. Clin Infect Dis 2011;52:493-506.
31. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
32. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352.